查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594387

骨髓发育不良症候群市场：按给药途径、药物类别划分 - 2025-2030 年全球预测

Myelodysplastic Syndrome Market by Route of Administration (Oral, Parenteral), Drug Class (Alkylating Agents, Cytotoxic Antibiotics, Topoisomerase Inhibitors) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

骨髓发育不良症候群市场价值2023年为25.9亿美元，预计到2024年将达到28.4亿美元，复合年增长率为10.07%，预计到2030年将达到50.7亿美元。

骨髓发育不良症候群(MDS) 是一组不同的骨髓疾病，其特征是造血功能低下，导致血球异常。该领域的分析范围包括了解诊断方法、治疗方法和患者人口统计数据，这对于制定有针对性的行销策略至关重要。对MDS进行研究的必要性源自于MDS盛行率的增加，特别是在人口老化中，以及中等存活率，这需要更好的治疗方法。最终用途范围包括管理 MDS 治疗和护理的医院、癌症中心和专科诊所。

主要市场统计
基准年[2023] 25.9亿美元
预测年份 [2024] 28.4亿美元
预测年份 [2030] 50.7亿美元
复合年增长率（%） 10.07%

根据市场洞察，在药物开发的进步和对疾病基因组成的更好理解的推动下，对有效治疗和支持性护理服务的需求不断增长是一个关键的成长要素。策略伙伴关係和合作研究工作正在为创新药物配方和治疗方法开闢新途径，为相关人员提供有利的机会。然而，高昂的治疗成本、临床测试的复杂性和严格的监管要求等限制带来了重大挑战。此外，MDS 的异质性使治疗效果和市场可预测性变得复杂。

为了利用这些机会，公司应该专注于创新标靶治疗、利用生物标记研究以及开发具有成本效益的诊断和治疗方法，以改善患者的治疗结果。了解区域市场动态和投资新兴市场也被认为是有益的。需要透过相关人员的参与和教育措施来解决某些人群的有限患者入组和诊断不足等挑战。基因检测和精准医学的创新具有开拓的潜力。最终，使产品开发与患者需求和市场要求保持一致对于确保在不断变化的市场环境中持续成长和竞争优势至关重要。研究和开发必须继续优先考虑以患者为中心的方法，以提高整体市场的永续性和临床成功。

市场动态：揭示快速发展的骨髓发育不良症候群市场的关键市场洞察

骨髓发育不良症候群市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 老年人口增加，此病发生率增加
    • 改善医疗服务以及干细胞移植和放射线治疗的进步
    • 新治疗方法的可用性和可及性
  • 市场限制因素
    • 新疗法的高成本
  • 市场机会
    • 开发强大的药物管道
    • 报销政策等政府支持措施
  • 市场问题
    • 新疗法的复杂性和异质性

波特的五力：驾驭骨髓发育不良症候群市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解骨髓发育不良症候群市场的外部影响

外部宏观环境因素在塑造骨髓发育不良症候群市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解骨髓发育不良症候群市场的竞争格局

对骨髓发育不良症候群市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：骨髓发育不良症候群市场的供应商绩效评估

FPNV定位矩阵是评估骨髓发育不良症候群市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製骨髓发育不良症候群市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，骨髓发育不良症候群市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争格局中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境，主要企业的广泛资料，评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 老年人口增加和综合症发生率增加
      • 改善医疗服务以及干细胞移植和放射治疗的进步
      • 新治疗方法的可用性和可及性
    • 抑制因素
      • 新治疗方法的高成本
    • 机会
      • 开发强大的药物管道
      • 退费政策等政府支持措施
    • 任务
      • 新疗法的复杂性和多样性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章骨髓发育不良症候群市场：依给药途径

  • 介绍
  • 口服
  • 胃肠外的

第七章骨髓发育不良症候群市场：依药物类别

  • 介绍
  • 烷化剂
  • 细胞毒性抗生素
  • 拓朴异构酶抑制剂

第八章北美和南美骨髓发育不良症候群市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太骨髓发育不良症候群市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲骨髓发育不良症候群市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Amgen Inc.
  • Bellicum Pharmaceuticals
  • BioLineRx Ltd.
  • BluePoint Laboratories
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Johnson & Johnson
  • MEI Pharma Inc.
  • Novartis AG
  • Onconova Therapeutics, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-036C5CF3A8C0

The Myelodysplastic Syndrome Market was valued at USD 2.59 billion in 2023, expected to reach USD 2.84 billion in 2024, and is projected to grow at a CAGR of 10.07%, to USD 5.07 billion by 2030.

Myelodysplastic Syndrome (MDS), a group of diverse bone marrow disorders, is characterized by ineffective hematopoiesis leading to blood cell abnormalities. The analytical scope of this domain involves understanding its diagnostic methods, treatments, and patient demographics, essential for creating targeted marketing strategies. The necessity of research in MDS arises from its increasing prevalence, notably among the aging population, and the moderate survival rates which demand better therapeutic solutions. The application scope touches on pharmaceutical advancements, personalized medicine, and novel diagnostic technologies, while the end-use scope encompasses hospitals, cancer centers, and specialized clinics equipped to manage MDS treatment and care.

KEY MARKET STATISTICS
Base Year [2023] USD 2.59 billion
Estimated Year [2024] USD 2.84 billion
Forecast Year [2030] USD 5.07 billion
CAGR (%) 10.07%

Market insights reveal that the rising demand for effective therapeutics and supportive care services are key growth factors, driven by advancements in drug development and an increased understanding of the disease's genetic makeup. Strategic partnerships and collaborative research efforts are opening new avenues for innovative drug formulations and treatment methodologies, offering lucrative opportunities for stakeholders. However, limitations such as the high cost of treatment, the complexity of clinical trials, and stringent regulatory requirements pose significant challenges. Moreover, the heterogeneity of MDS complicates treatment efficacy and market predictability.

To harness these opportunities, businesses should focus on innovation in targeted therapies, leveraging biomarker research, and developing cost-effective diagnostics and treatments to improve patient outcomes. Understanding regional market dynamics and investing in emerging markets could also be beneficial. Challenges such as limited patient registries and underdiagnosis in certain populations need addressing through stakeholder engagement and educational initiatives. Innovations in genetic testing and precision medicine present untapped potential. Ultimately, aligning product development with patient needs and market requirements will be crucial for sustained growth and competitive advantage in the evolving MDS market landscape. Research and development must continue to prioritize patient-centric approaches to enhance overall market sustainability and clinical success.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Myelodysplastic Syndrome Market

The Myelodysplastic Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising geriatric population and increasing incidence of the syndrome
    • Improvements in healthcare services and advancements in stem cell transplantation and radiation therapy
    • Easy of availability and access to novel treatments
  • Market Restraints
    • High cost of novel therapeutics
  • Market Opportunities
    • Development of strong drug pipeline
    • Supportive government initiatives such as reimbursement policies
  • Market Challenges
    • Complexity and heterogeneity of novel treatment

Porter's Five Forces: A Strategic Tool for Navigating the Myelodysplastic Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Myelodysplastic Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Myelodysplastic Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Myelodysplastic Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Myelodysplastic Syndrome Market

A detailed market share analysis in the Myelodysplastic Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Myelodysplastic Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Myelodysplastic Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Myelodysplastic Syndrome Market

A strategic analysis of the Myelodysplastic Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Myelodysplastic Syndrome Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Bellicum Pharmaceuticals, BioLineRx Ltd., BluePoint Laboratories, Bristol-Myers Squibb Company, Celgene Corporation, Dr. Reddy's Laboratories, Eli Lilly and Company, Johnson & Johnson, MEI Pharma Inc., Novartis AG, Onconova Therapeutics, Inc., Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Myelodysplastic Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Drug Class, market is studied across Alkylating Agents, Cytotoxic Antibiotics, and Topoisomerase Inhibitors.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising geriatric population and increasing incidence of the syndrome
      • 5.1.1.2. Improvements in healthcare services and advancements in stem cell transplantation and radiation therapy
      • 5.1.1.3. Easy of availability and access to novel treatments
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of novel therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of strong drug pipeline
      • 5.1.3.2. Supportive government initiatives such as reimbursement policies
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity and heterogeneity of novel treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Myelodysplastic Syndrome Market, by Route of Administration

  • 6.1. Introduction
  • 6.2. Oral
  • 6.3. Parenteral

7. Myelodysplastic Syndrome Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Alkylating Agents
  • 7.3. Cytotoxic Antibiotics
  • 7.4. Topoisomerase Inhibitors

8. Americas Myelodysplastic Syndrome Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Myelodysplastic Syndrome Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Myelodysplastic Syndrome Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Bellicum Pharmaceuticals
  • 4. BioLineRx Ltd.
  • 5. BluePoint Laboratories
  • 6. Bristol-Myers Squibb Company
  • 7. Celgene Corporation
  • 8. Dr. Reddy's Laboratories
  • 9. Eli Lilly and Company
  • 10. Johnson & Johnson
  • 11. MEI Pharma Inc.
  • 12. Novartis AG
  • 13. Onconova Therapeutics, Inc.
  • 14. Otsuka Pharmaceutical Co., Ltd.
  • 15. Sun Pharmaceutical Industries Inc.
  • 16. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. MYELODYSPLASTIC SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. MYELODYSPLASTIC SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. MYELODYSPLASTIC SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. MYELODYSPLASTIC SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MYELODYSPLASTIC SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MYELODYSPLASTIC SYNDROME MARKET DYNAMICS
  • TABLE 7. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY CYTOTOXIC ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM MYELODYSPLASTIC SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. MYELODYSPLASTIC SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 101. MYELODYSPLASTIC SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023